Muste Cathy A, Pickel Thomas C, Bolduc Philippe N, Peterson Emily A, Gu Chungang, Cook Brendon E
Drug Metabolism and Pharmacokinetics, Biogen, Cambridge, Massachusetts 02142, United States.
ASO Development, Biogen, Cambridge, Massachusetts 02142, United States.
ACS Omega. 2025 Jun 5;10(23):24768-24777. doi: 10.1021/acsomega.5c01780. eCollection 2025 Jun 17.
PET imaging of intrathecally dosed ASO neurology drugs is challenging due to the long time needed to achieve steady-state brain distribution, making the use of a simple F tag impossible with its short radioactive half-life. To overcome this challenge, a pretargeted imaging solution has been developed in which an ASO tagged with a tetrazine is dosed intrathecally, and after 24 h a reactive -cyclooctene (TCO) tagged with F is dosed intravenously. The two molecules form a click-chemistry adduct, allowing for PET imaging scans immediately following F-TCO administration. Although it has been demonstrated that TCOs can be relatively stable in vivo, they rapidly isomerize to -cyclooctenes (CCOs) in cell culture media and "aged" plasma, making many DMPK experiments challenging to interpret and not representative of the in vivo stability. The predominant cause of isomerization was determined to be thiamine degradation product(s) in media such as DMEM. Several techniques to overcome the challenges of in vitro and ex vivo isomerization during analytical experiments are herein proposed, such as the use of custom media and/or fresh plasma, adding antioxidants, using surrogate molecules, and using TCO trapping agents. These findings and techniques may also be relevant to other applications in which TCOs are incubated in thiamine-containing cell culture media.
鞘内注射反义寡核苷酸(ASO)神经学药物的正电子发射断层扫描(PET)成像具有挑战性,因为达到稳态脑部分布需要很长时间,这使得使用具有短放射性半衰期的简单F标记变得不可能。为了克服这一挑战,已经开发了一种预靶向成像解决方案,其中鞘内注射用四嗪标记的ASO,24小时后静脉注射用F标记的反应性环辛烯(TCO)。这两种分子形成点击化学加合物,使得在注射F-TCO后立即进行PET成像扫描成为可能。尽管已经证明TCOs在体内可以相对稳定,但它们在细胞培养基和“老化”血浆中会迅速异构化为环辛烯(CCOs),这使得许多药物代谢动力学(DMPK)实验难以解释,且不能代表体内稳定性。异构化的主要原因被确定为培养基(如DMEM)中的硫胺素降解产物。本文提出了几种在分析实验中克服体外和离体异构化挑战的技术,如使用定制培养基和/或新鲜血浆、添加抗氧化剂、使用替代分子以及使用TCO捕获剂。这些发现和技术也可能与其他在含硫胺素的细胞培养基中孵育TCOs的应用相关。